T. Werner, T. Drüke, A. Hahn, M. Scherf
Genomatix Software Gmb
Personalized medicine aims at understanding genetic differences and reactions of individual patients in order to devise optimized individual therapies. This requires first recognizing genetic variances in patients and how these affect reactions to disease and therapy. There is a multitude of genetic variations (biological noise) most of which are not relevant for a particular disease or treatment. Therefore, biomarker-based diagnostics are commonly used to identify disease-relevant changes or differences. However, existing biomarkers are not sufficient or specific enough for personalized medicine approaches. Additional and more specific biomarkers are required.
PM13 focuses on generation of new biomarkers based on molecular data (-omics-based). Initial data sets are provided by m4 and international partners and will be analyzed with respect to regulatory networks. Such networks not only allow monitoring genetic and physiological changes but also in many cases elucidation of the underlying molecular causes for observed changes. These results in turn are the foundation upon which new and relevant biomarkers can de detected and validated. By merging such results and predictions with corresponding clinical data and integration into the m4 DIS portal (web-site) new biomarker candidates are being brought back to the clinical environment. New candidates for diagnostic procedures derived this way can then be tested for diagnostic value in cooperation with clinical partners in the m4 trial centers.